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Uptake and metabolism of cisplatin by rat kidney
ROBERT SAFIRSTEIN, PETER MILLER, and JOSEPH B. GUTTENPLAN
Division of Nephrology, Department of Medicine, Mount Sinai School of Medicine, and Department of Biochemistry, New York University
Dental Center, New York, New York
Uptake and metabolism of cisplatin by rat kidney. Cisplatin, an
effective antineoplastic agent, is toxic to the kidney. Since the kidney's
vulnerability to cisplatin may originate in its ability to accumulate and
retain platinum to a greater degree than other organs, we studied the
characteristics of the renal accumulation of platinum and investigated
the nature of intracellular platinum. Cisplatin and ethylenediammine-
dichloroplatinum, nephrotoxic and antineoplastic liganded platinum
compounds, were concentrated in rat renal cortical slices fivefold above
medium concentration. Platinum uptake was energy- and temperature-
dependent and could be inhibited by drugs which inhibit base transport.
The organic anions para-aminohippurate and pyrazinoate did not re-
duce renal slice platinum uptake. Unbound platinum in the blood and
urine was predominantly cisplatin but unbound platinum in kidney
cytosol was not. This latter compound, in contrast to cisplatin, was not
active as a mutagen. These studies suggest that the kidney accumulates
platinum in part by transport or specific binding to the base transport
system in the kidney and biotransforms it intracellularly. Unbound
platinum in the cell is not cisplatin and may no longer be toxic.
Captation et métabolisme du cisplatine par le rein de rat. Le cisplatine,
un agent anti-néoplasique efficace, est toxique pour le rein. Puisque la
vulnérabilité du rein au cisplatine pourrait provenir de sa capacité
d'accumuler et de conserver le platine a un degre plus élevé que
d'autres organes, nous avons étudié les caractéristiques de l'accumula-
tion rénale de platine et cherché Ia nature du platine intra-cellulaire. Le
cisplatine et l'éthylènediamminedichloroplatine, des composes nephro-
toxiques et anti-neoplasiques lies au platine, étaient concentrés dans
des tranches corticales rénales de rat cinq fois plus que Ia concentration
du milieu. La captation du platine était dependante de l'énergie et de Ia
temperature, et pouvait être inhibée par des médicaments qui inhibent
le transport des bases. Les anions organiques para-aminohippurate et
pyrazinoate ne diminuaient pas Ia captation du platine par les tranches
rénales. Le platine non lie dans le sang et l'urine était de facon
predominante du cisplatine, mais le platine non lie dans le cytosol de
rein n'en était pas. Ce dernier compose, contrairement au cisplatine,
n'Ctait pas actif en tant que mutagène. Ces etudes suggèrent que le rein
accumule le platine en partie par un transport ou par une liaison
specifique au système de transport des bases dans le rein, et Ic
biotransforme dans les cellules. Le platine non lie dans Ia cellule n'est
pas du cisplatine et pourrait ne plus être toxique.
Cisplatin, a platinum-containing coordination complex, is an
antitumor agent with proven efficacy against many solid tu-
mors. The chief dose-limiting side effect of cisplatin is its
pronounced nephrotoxicity which occurs at doses lower than
those that damage other organs [1, 21. Acute renal failure can
occur with a single dose of cisplatin [3] and repeated exposure
causes chronic renal failure [4, 5]. Relevant perhaps to the
nephrotoxicity of cisplatin are the observations that the kidney
accumulates and retains platinum to a greater extent than other
organs, and it is the kidney that is the predominant excretory
organ for cisplatin [6, 7]. Although the kidney's vulnerability
may originate from its role in the excretion and uptake of
platinum, many aspects of the renal handling of cisplatin are not
understood.
In the rat, 50% of injected cisplatin is excreted in the urine 24
hr after its administration [6, 7] and most of excreted platinum
appears in the urine within the first hour [8]. Although platinum
is extensively bound to plasma proteins [9], free platinum in the
plasma is mainly cisplatin; by virtue of its low molecular weight
and uncharged character, cisplatin should be freely filtered at
the glomerulus [10]. Plasma clearance of unbound platinum is at
or slightly above inulin clearance [11—13]. Thus cisplatin enters
the urinary space predominantly by filtration and, possibly, by
secretion.
The process by which cisplatin enters the renal cell is
unknown. The renal accumulation of platinum in vivo is a rapid
process which is completed 1 to 6 hr after it is given [6, 14].
Twenty-four hours after a 5 mg/kg of body wt dose of cisplatin
to the rat, its kidney contains nearly 1% of the administered
dose [15] and concentrates platinum eightfold above the plas-
ma concentration [6]. Platinum can be found in many subcellu-
lar sites with most of it present in the cytosolic compartment
[14]. A surprisingly large amount of intracellular platinum is not
protein bound (30 to 50%) and neither the chemical form nor
biologic activity of this portion of cell platinum are known at the
present time [14].
The present studies were performed to characterize further
the process of renal accumulation of platinum and also to
investigate the chemical form and biologic activity of unbound
platinum in the renal cell.
Methods
Isotopes. Two radiolabeled platinum compounds were used.
(l9smpt) Cisplatin in isotonic saline (sp act 145 mCi/mmole) was
made available through I. D. Hoeschele, Ph.D., and F. F.
Knapp, Jr., Ph.D. at Oak Ridge National Laboratory, Oak
Ridge, Tennessee. Nonradioactive cisplatin was obtained
through the drug synthesis and chemistry branch, National
Cancer Institute, Bethesda, Maryland. Since t95mPt has a short
half-life and radiolabeled cisplatin was synthesized at irregular
intervals, '4C-labeled ethylenediamminedichioroplatinum,
Pt('4C-en)Cl2, was used to facilitate the in vitro studies. This
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platinum-containing compound is both nephrotoxic and anti-
neoplastic [16], undergoes similar nucleotide reactions [171, and
is retained by the kidney to a similar extent as cisplatin [15]. It
differs from cisplatin in that it contains an ethylene bridge
between the primary amines of cisplatin. Pt('4C-en)C12 was
prepared from 14C-labeled ethylenediamine, sp act 20 to 40
mCi/mmole (Amersham, Arlington Heights, Illinois) and
PtK2CI4 by the route suggested by Dhara [18]. Pt('4C-en)C12
was prepared with a specific activity of 300 to 350 pCi/mM; its
purity was confirmed by ascending paper chromatography or
HPLC (see below). [3H-methoxy]-inulin was obtained with a
specific activity of 100 to 500 mCi/g (New England Nuclear
Corp., Boston, Massachusetts).
Kidney s/ice studies. Rat cortical tissue slices (15 to 30 mg)
were prepared using a hand-held microtome, weighed and
incubated in a Cross and Taggart buffer system consisting of
sodium chloride (77 mM), potassium chloride (36 mM), sodium
acetate (10mM), sodium phosphate (7mM, pH 7.4), and calcium
chloride (1 mM) [19]. In most experiments PAH (6.7 x 10 M)
was included in the incubation medium.
The slices were incubated in a water-bath shaker (New
Brunswick, Scientific, New Brunswick, New Jersey) set at 90
to 100 cycles/mm under 100% oxygen atmosphere at 23°C. Each
incubation vial contained at least 1 Ci of '4C-labeled Pt(en)C12
or (I95mpt)cisplatin The uptake of the platinum analogues was
studied over a concentration range of 10—6 to i03 M. At 30, 60,
120, and 240 mm the vials were removed and placed on ice. The
slices were reweighed and homogenized in distilled water. This
protocol was used to observe the effects of reduced temperature
(4°C), anoxia (N2 atmosphere), and pH (6—8) on uptake. In
experiments where uptake was measured in the presence of
inhibitors, the slices were incubated for 2 hr in media modified
by adding inhibitors in a phosphate buffer (67 mM) and adjusted
to pH 7.4 after the addition of the inhibitor. Control slices were
incubated in media containing equal volumes of this buffer
without an added drug. Each of the platinum analogues was
stable in the incubation medium with or without the added
inhibitors as determined by HPLC (see below). 3H-inulin was
added to the incubation medium in one study to correct for slice
extracellular fluid platinum content. l95mptor '4C activity in the
tissue and medium was determined in a spectrophotometer
(Packard TRI-CARB, Downers Grove, Illinois) using a com-
mercial scintillant (Budget Solve, Research Products Interna-
tional, Elks Grove, Illinois) and the '4C window of the spectro-
photometer. The counting efficiency for [l9smPt] under these
conditions exceeds 90% [10]. Platinum bound to tissue proteins
was determined in decolorized Protosol (New England Nuclear
Corp., Boston, Massachusetts) digests of 7% trichloroacetic
acid precipitates of the slice homogenates. PAH in homogenate
and medium was determined by a modification of the method of
Bratton and Marshall [201. Tissue uptake was calculated as the
ratio of tissue (CPM/g tissue weight) to medium (CPM/ml)
platinum concentration.
Cisplatin metabolism. A total of eight male Sprague-Dawley
rats were given 5 mg/kg cisplatin (1 mg/mI) 0.9% NaCI, 10 to 50
Ci [l95mPtIcisplatin/ml) i.p. The animals were placed in metal
metabolic cages and urine samples were collected for up to 24
hr after injection. In preliminary experiments performed in five
rats given 5 mg/kg cisplatin, as above, platinum in the cortical
homogenates represented 97.1 0.4% of the total platinum in
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Fig. 1. Pt('4C-en)C12 uptake by kidney slices incubated for up to 240
mm in the presence of 60 /.LM Pt('4C-en)C12. Each point is the mean of
four determinations. The lower curve is the Pt('4C-en)C12 slice with
uptake corrected (O---O) for extracellular Pt('4C-en)C12 determined
using 3H-inulin as an extracellular marker; •—• refers to uncorrected
uptake.
the kidney 24 hr after the cisplatin injection. We, therefore,
turned our attention to the cortical form of the nonprotein
bound platinum. In these preliminary studies no difference in
the chromatographic appearance and biologic activity of excret-
ed platinum was observed when collected under oil or kept on
ice during this 24-hr period. The rats were anesthetized and the
kidneys were removed after intra-arterial perfusion of 10 to 20
ml of cold 0.25 M sucrose in 0.1 M phosphate buffer (pH 7.4).
Homogenates of rat kidney cortex were prepared in the same
buffer (3:1 W/V) in the cold using teflon pestles and glass tubes
(TRI-R Instruments, Inc., Rockville Center, New York). The
homogenate was centrifuged (Sorvall RC2B, Newton, Connect-
icut) at 4°C at X800g x 2, and X 12,000g x 2 for 10 mm each.
The supernatant was then spun at x 105,000g (Beckman L5-75,
Beckman Instruments, Palo Alto, California) for 60 mm. An
ultrafiltrate of the postmicrosomal supernatant fraction (the
fraction containing the most platinum) was prepared in a cold
room using a micropartition system and YMP filters, molecular
weight cutoff 30,000 daltons (Amicon MPS- 1, Amicon Corp,
Danvers, Massachusetts). These membranes retain 93% of the
proteins present in the cytosolic fractions. In some experiments
these ultrafiltrates were filtered again through 500-dalton cutoff
filters (Amicon UMO5) using a stirred ultrafiltration cell (Ami-
con Model 3). Greater than 95% of cisplatin added to ultrafil-
tered cytosols of untreated animals is passed chromatographi-
cally unchanged through these filters. When cisplatin was
added to kidney cytosol of control rats and an ultrafiltrate was
prepared immediately after its addition, 87% of the platinum
added was recovered chromatographically unchanged in the
ultrafiltrate.
High performance liquid chromatography (HPLC). HPLC
was performed on a system consisting of a solvent delivery
system (Waters, M45, Milford, Massachusetts) using a partisil-
10 SCX strong cation exchange column (Whatman, Clifton,
New Jersey). The details of this system have been published
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previously [10]. Samples were injected. The column was eluted
with 0.012 M sodium acetate, pH 3.5 at a flow rate of 0.5 ml/min
and fractions were collected every 0.4 mm using a fraction
collector (Model 2112, LKB, Rockville, Maryland). I9smp
activity was determined in the fractions using a scintillation
counter.
Muta genesis. Bacterial mutagenesis was assayed by the
standard Ames test without any metabolic activation system,
using Salmonella typhimurium TA 100 (kindly supplied by Dr.
B. Ames, Berkeley, California) [21]. This mutant strain has an
absolute requirement of histidine for growth. The test measures
reversion to histidine independence. Bacteria (0.1 ml of an
overnight culture) are mixed with a test substance and overlaid
onto histidine-poor agar. The plates are incubated at 37°C for 2
days and each revertant gives rise to a visible colony. Colonies
are counted using a colony counter (Artek Systems Corpora-
tion, East Farmingdale, New York). Spontaneous revertants,
which arise on control plates without added mutagen, are
subtracted from all revertant numbers.
Ultrafiltrates of cell cytosol were prepared as above using
(Amicon YMB) filters which were washed beforehand with the
homogenate buffer. This washing step was necessary to remove
the sodium azide, a mutagen, used as a preservative in these
filters. In addition to the mutagenesis assay, the ultrafiltrates
were combined with diluted bacteria (5 x 106 dilution) and
placed onto histidine-containing minimal agar to determine
toxicity. Toxic fractions were diluted and mutagenesis reas-
sayed under conditions of minimal (10%) toxicity. This proce-
dure was necessary since a reduction in the number of viable
colonies may result in a reduction in the numbers of revertant
colonies observed.
Results
The results of the slice uptake of Pt['4C-en]C12 are shown in
Figure 1. Platinum content of the slice was fivefold above
medium content at 4 hr. Nearly half (48.8 1.5%) of the total
Pt['4C-en]C12 content was protein-bound. When uptake was
corrected for slice extracellular fluid and medium trapping little
change in the slice to medium ratios was found. In experiments
using [l9smpt]cisplatin 2-hr uptakes did not differ significantly
23°C Table 1. Effect of anoxia and various inhibitors on kidney uptake of
Pt('4C-en)Cl2 (60 m)
.Incubation conditions
M
S/M ratio°
PControl Inhibitor
N2 2.61 0.13
(8)
1.69 0.4
(8)
<0.001
2,4 Dinitrophenol (10) 2.50 0.26
(4)
1.62 0.09
(6)
<0.001
Carbonylcyanide m-chloro- 2.73 0.06 1.60 0.06 <0.001
phenyl-hydrazone (10) (4) (4)
Pyrazinoate (10-2) 3.33 0.31
(4)
3.24 0.25
(4)
NS
p-Aminohippurate (10-2) 3.34 0.39
(4)
3.31 0.05
(4)
NS
Probenecid (10_2) 2.99 0.12
(7)
1.63 0.08
(7)
<0.001
Mepiperphenidol (102) 3.33 0.15
(4)
1.58 0.02
(4)
<0.001
Tolazoline (10-2) 3.33 0.15
(4)
1.73 0.04
(4)
<0.001
Thiamine (102) 3.32 0.27
(4)
2.38 0.08
(4)
< 0.025
Tetraethylammonium (10-2) 3.33 0.15
(4)
2.72 0.17
(4)
<0.05
° S/M is slice-to-medium ratios (mean 5EM) after 2 hr of incubation;
the number in parenthesis refers to the number of slices.
from those observed with Pt(en)Cl2 (results not shown). Tissue
uptake of Pt(en)C12 or cisplatin showed no saturation at drug
concentrations up to 3 mrvi. It was difficult to study higher
concentrations of the liganded platinum compounds because of
their relative insolubility at higher concentrations. Slice:me-
dium ratios of cisplatin at pH 7 (2.70 0.12) were not different
from values at pH 6 (2.60 0.02) or 8 (2.74 0.12). Platinum
uptake was markedly reduced when slices were incubated at
4°C (Fig. 2).
Table 1 summarizes the results of the inhibition studies.
Dinitrophenol (DNP) l0 M and carbonylcyanide m-chloro-
phenylhydrazone (CCCP) l0 M, uncouplers of oxidative
phospharylation, reduced Pt(en)Cl2 uptake by 30 to 40%, as did
incubating tissue slices under nitrogen. p-Aminohippurate
(PAH) and pyrazinoate, organic anions, failed to affect
Pt(en)Cl2 uptake at concentrations up to 102 M. A series of
organic bases, tolazoline, TEA, mepiperphenidol and thiamine,
inhibited Pt(en)C12 uptake to varying degrees. Probenecid inhib-
ited Pt(en)C12 uptake. At doses of 102 M, while probenecid and
mepiperphenidol virtually eliminated PAH uptake, tolazoline
inhibited Pt(en)C12 and cisplatin uptake without affecting PAH
uptake (Table 2).
Table 3 summarizes the results of experiments designed to
detect inhibition of Pt( '4C-en)C12 uptake into kidney slices using
lower doses of the inhibitors identified in Table 1. It can be seen
that all inhibitors reduce uptake at l0 M. Of particular interest
is the effect of mepiperphenidol which inhibits uptake at i0
and iO without reducing PAR uptake. Thus, both tolazoline
and mepipheridol reduce platinum uptake selectively without
reducing PAH uptake.
Figure 3 depicts the chromatographic pattern of administered
i95mPt in kidney tissue and urine. The chromatographic behav-
ior of platinum in the urine is the same as that of cisplatin.
l9smp in the cytosolic ultrafiltrate on the other hand eluted
earlier than cisplatin. Another platinum containing peak
50
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Fig. 2. Effect of temperature on Pt('4C-en)C12 uptake by renal tissue
slices.
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Table 2. Effect of mepiperphenidol and tolazoline on cisplatin and
PAH uptake in kidney slices
SIM ratio
('95)Ptcisp1atin PAH
—
Control 2.77 0.11
(8)
12.3
(4)
0.6
Mepiperphenidol (102 M) 2.08 0.05"
(8)
2.54
(4)
0.03"
Tolazoline (10—2 M) 2.17 0.08"
(8)
13.0
(4)
1.2
P < 0.001 compared to control.
amounting to less than 15% of the recovered platinum eluted
later than the principal platinum peak. This later peak was not
the monoaquo or diaquo species of platinum which elutes at a
later time [10]. More than 95% of the platinum present in the
original ultrafiltrate passed through a 500-dalton cutoff filter.
The biologic behavior of platinum in kidney cytosolic ultrafil-
trates was different from excreted platinum or cisplatin. In
contrast to cisplatin [22] and excreted platinum [10], unbound
intracellular platinum was no longer mutagenic (line 2, Table 4).
Ultrafiltrates of kidney cytosols from untreated rats augmented
cisplatin mutagenicity (compare lines 3 and 4, Table 4). To
determine if the mutagenic activity of cisplatin was lost during
the preparation of the cytosolic ultrafiltrates, cisplatin was
added to kidney homogenates of untreated rats, and cytosolic
ultrafiltrates were prepared in the same manner as before. The
ultrafiltrates were then plated and mutagenicity was deter-
mined. The mutagenic activity was the same as that expected
for cisplatin at a concentration equivalent to the platinum
concentration in the sample. Therefore, the workup procedures
for the kidney cytosolic ultrafiltrate did not lead to the deactiva-
tion of cisplatin.
Discussion
These studies demonstrate that renal slices accumulate cis-
platin and a related platinum containing analogue, Pt(en)C12, up
to five times above their extracellular concentrations, Four
characteristics of this renal accumulation were observed: (1)
maximum platinum uptake depends on the presence of normal
oxygen utilization; (2) a significant portion of the tissue plati-
num is protein-bound; (3) platinum uptake was not saturable, at
least up to 3 m concentrations; and (4) platinum uptake could
be inhibited partially and specifically by drugs. Drugs which
compete in the kidney for the transport of organic acids, PAH
and pyrazinoate, had no effect on the transport of cisplatin or
Pt(en)C12. On the other hand, drugs known to be transported by
the organic base transport system in the kidney such as
mepiperphenidol, tetraethylammonium, tolazoline, and thia-
mine all reduced cisplatin uptake significantly. Of interest is the
rather specific inhibitory effect observed with tolazoline and
mepiperphenidol on platinum uptake since they alone inhibited
cisplatin uptake without reducing PAH uptake.
Probenecid, like many of the drugs tested, inhibited both
PAH and cisplatin uptake. While probenecid reduces the up-
take of the bases 1-methorphan [231 and tetraethylammonium
[24], and thus might be expected to reduce cisplatin uptake on
that basis, other effects of probenecid should be considered.
Probenecid (1 mM) can inhibit glycine conjugative reactions
[251, inhibit acetylation of choline and sulfanilamide and cholin-
esterase, a serine protease [26] and inhibit 15-hydroxyprosta-
glandin dehydrogenase [27]. Of interest are experiments which
demonstrate that the reduction by probenecid of amino acid
uptake by kidney slices [24] and digitoxin uptake by liver slices
[28] is due to an inhibitory effect on their metabolism rather
than inhibition of their transport. Thus, probenecid may reduce
platinum uptake by interfering with its biotransformation by the
cell (see below). Taken together, the results of the uptake
studies and the effect of the various inhibitors suggest that
cisplatin accumulation by the kidney may involve a specific
interaction with the base carrier system as well as intracellular
biotransformation of cisplatin.
After cisplatin entered the renal cell its form was altered.
Unbound cell platinum behaved both chromatographically and
biologically different from administered or excreted cisplatin
[10]. The stability of cisplatin in the extracellular fluid as
opposed to its instability in the intracellular fluid seems to fit
well with the known chemistry of cisplatin. Cisplatin is a planar
coordination complex of platinum with platinum in the +2
oxidation state. The chloride ligands are labile and it is the
lability of these chloride ligands which is important to the
reactivity, and toxicity, of the cisplatin molecule [16]. At the
relatively low cell concentrations of chloride, about 20 mM [29],
substitution of the chloride ligands of the cisplatin molecule
with water is facilitated converting cisplatin to positively
charged reactive and toxic aquated derivatives [30—32]. The
chromatographic behavior of unbound cell platinum was indeed
different from the parent compound. The early elution of this
compound from the cationic exchange column at the pH of the
elution buffer suggests that the compound in the cell is neutral
and formed by nucleophilic substitution of the chloride without
change in charge. Although glutathione would seem to be a
likely candidate for such interaction, a recent publication
reports that only a small fraction (30%) of cellular platinum was
associated with glutathione [33].
Another characteristic of this unbound platinum metabolite is
its lack of mutagenicity (Table 4). Mutagenic compounds usual-
ly react with or can be metabolically converted to compounds
which react with electron-rich centers, such as neutral nitro-
gens or sulfhydryl groups. Several of these electron-rich centers
exist in DNA and can react with mutagenic compounds to form
DNA adducts. These adducts by a variety of mechanisms cause
errors during DNA replication that lead to mutations [21]. Since
the electrophilic reactivity of cisplatin is believed to be respon-
sible for its mutagenic activity and since the toxicity of platinum
coordination complexes is correlated with their mutagenicity
[341, the loss of such activity may indicate that the intracellular
platinum compound is no longer toxic. Confirmation of this will
require isolation and identification of this compound found in
the cell.
The results of these experiments suggest two possible ap-
proaches to reducing cisplatin nephrotoxicity: First, it seems
possible to reduce platinum uptake in vivo and thereby de-
crease toxicity. Second, and more speculative, if the inactive
platinum compound found in renal cells is formed by an
enzyme-mediated process, the levels of this enzyme might be
enhanced by pretreatment with appropriate agents. This ap-
proach has been reported to enhance the levels of renal cell
ligandin and ameliorate the nephrotoxicity of HgCI2 [35].
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Table 3. Dose-dependent inhibition of kidney slice Pt('4C-en)C12 and PAH uptake by tolazoline mepiperphenidol, thiamine, and probenecid
Inhibitor
Conc.
M
No. of
slices
Pt('4C-en)C12
S/M ratio P
No. of
slices
PAH
S/M ratio P
Control 20 3.12 0.10 14 12.9 1.01
Tolazoline 10-2lOi0
7
4
4
1.60 0.08
2.62 0.06
3.14 0.19
< 0.001
< 0.05
NS
7
3
3
13.2 1.9
l5.3 3.4
22.2 4.5
NS
NS
< 0.01
Mepiperphenidol 10—2lO
1O
8
4
4
1.76 0.05
2.49 0.11
2.64 0.12
< 0.001
< 0.025
<0.05
11
3
3
0.49 0.13
13.1 0.70
13.2 1.40
< 0.001
NS
NS
Probenecid 10—210i0
8
4
4
1.63 0.07
2.57 0.17
3.14 0.19
< 0.001
< 0.05
NS
8
4
4
Not detecteda
Not detected
Not detected
Thiamine 10-2iOlO
4
4
4
2.38 0.08
2.51 0.10
2.71 0.05
< 0.005
< 0.025
NS
Not assessedb
Not assessed
Not assessed
Abbreviations: S/M ratio, slice-to-medium ratios (mean SEM) after 2 hr of incubation; NS, not significant.
a PAH concentration in homogenates fell below the level of detection.
b PAH was not added to the incubation medium.
Fig. 3. Chromarogram of'95"Pt in injectate (panel A), tissue (panel B),
and urine (panel C). Panel A—150 p.1 injection of 1.8 ,ag/m/ solution of
['95'"PtJ-cisplatin in 0.9% NaC/ eluted with 0.012 M Na acetate, pH 3.5,
at 0.5 mI/mm. Fractions were collected at 0.4-mm intervals. Panel B—
100 j.a.1 injection of ultrafllrrate (1.81 jig dsp/atm equivalent). Panel C—
50 j.d injection of urine containing platinum (142.4 jig/mI cisplatin)
collected 24 hr after the administration of cisp/atin.
Table 4. Effects of kidney cytosolic ultrafiltrates from untreated and
cisplatin-treated rats on revertant numbers in Salmonella
typhimurium TAIOO
Kidney fraction Treatment Addition Revertants
UF None None 262
UF Cisplatin None 307
UF None Cisplatin 1034
None None Cisplatin 643
Abbreviations: UF, ultrafiltrate of kidney cytosol; treatment, treat-
ment of the animals with cisplatin 5 mglkg body wt 24 hr prior to
isolation of kidneys [the platinum content of each plate was 3.4 x l0
moles of platinum (1.02 jig cisplatin equivalent in 0.6 ml of ultrafil-
trate)1; addition, the addition of 3.3 X iO moles of platinum (1.00 jig
cisplatin equivalent) to ultrafiltrate aliquot (0.6 ml) or directly to
incubate prior to plating; revertants, spontaneous revertants already
subtracted (precision between duplicate plates was within 25%).
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